Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

A randomized, blinded study of photobiomodulation in a mouse model of Alzheimer's disease showed no preventive effect

In conclusion, under the conditions of our experiment, we were unable to demonstrate any therapeutic effect of PBM for AD. This study calls for further evidence and caution when considering PBM as an effective treatment for AD.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

In a randomized, blinded study of 5xFAD mice, a mouse model of Alzheimer's disease, the authors tested near-infrared light (810 nm) given three times a week for five months during the early disease phase. The authors report no significant differences between sham and treated groups in behavioral tests or histological measures such as amyloid load, neuronal loss and microglial response. They conclude they could not demonstrate a therapeutic effect under their conditions.

Who or what was studied
5xFAD transgenic mice (a murine Alzheimer's disease model), treated from months 1 to 6 of life
Wavelengths
810 nm
Limits stated in the abstract
The study was conducted in mice under the specific conditions of one experiment, and the authors call for further evidence before drawing conclusions.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Photobiomodulation (PBM), the process of exposing tissue to red or near-infrared light, has become a topic of great interest as a therapy for diverse pathologies, including neurodegenerative disorders. Here, we aimed to evaluate the potential beneficial effect of PBM on Alzheimer's disease (AD) using behavioral and histological readouts from a well-established transgenic murine AD model (5xFAD mice) in a randomized and fully blinded long-term in-vivo study following GLP (Good Laboratory Practices) guidelines. The heads of the mice were illuminated with no (sham), low or high power 810 nm light, three times a week for 5 months from the first to the sixth month of life corresponding to the prodromal phase of the pathology. The results showed that there were no significant differences between the groups in behavioral tests, including the Morris water maze, novel object recognition, and Y-maze. Similarly, histological analyses showed no differences in amyloid load, neuronal loss or microglial response. In conclusion, under the conditions of our experiment, we were unable to demonstrate any therapeutic effect of PBM for AD. This study calls for further evidence and caution when considering PBM as an effective treatment for AD.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Wavelength
810 nm

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Near-infrared, Sham. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies